Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Daniel J GeorgeKrishnan RamaswamyHongbo YangQing LiuAdina ZhangAlexandra GreatsingerJasmina I IvanovaBetty ThompsonBirol EmirAgnes HongStephen J FreedlandPublished in: Prostate cancer and prostatic diseases (2024)
In the Medicare chemotherapy-naïve mCRPC population, 1L abiraterone was associated with worse OS versus enzalutamide in the overall population and among subgroups with older age and comorbidities, supporting findings from previous real-world studies and demonstrating a disparity in outcomes.